N/A
N=200
Early Progesterone Cessation After in Vitro Fertilization
Pregnant Women
Bottom Line
View on ClinicalTrials.gov: NCT01177904 ↗Enrolled (actual)
200
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Number of Bleeding Episodes — 8; 8 Episodes of bleeding
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Cease progsterone at 5 (Other); control group: progesterone 8 (Other)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- IVI Madrid
- Primary completion
- Jan 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Bleeding Episodes |
8; 8 | — |
Summary
There seems to be a general consensus on the supplementation of progesterone (P4) for luteal phase support (LPS) to all women after in vitro fertilization (IVF) treatment. However, there is no agreement about the precise duration of LPS.
Eligibility Criteria
Inclusion Criteria
- Patients who underwent ovarian stimulation using GnRH analogues,
- Fresh embryo transfer,
- LPS by vaginal micronized P4,
- Clinical pregnancy demonstrated by US and
- Informed consent signed.
Exclusion Criteria
Patients who had bleeding episodes before their first US because they are likely to continue P4 therapy without medical indication.
Data sourced from ClinicalTrials.gov (NCT01177904). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.